drugset / Trial / NCT00361218

Biological Markers of Response to Treatment in Major Depressive Disorder

NCT00361218

Phase 3 Completed 72 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or escitalopram).

Timeline

Start
2005-10
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Citalopram Small molecule Oral
Subject Escitalopram Small molecule Oral